公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2015 | Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer | YU-HSUAN CHEN ; Wei M.-F.; CHUN-WEI WANG ; Lee H.-W.; Pan S.-L.; Gao M.; SUNG-HSIN KUO ; ANN-LII CHENG ; Teng C.-M. | Cancer letters | 42 | 39 | |
2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
2016 | Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Radiology | 27 | 25 | |
2012 | Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy | Kuo Y.-H.; CHING-HUNG LIN ; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG ; Huang S.-M.; CHIUN HSU ; YEN-SHEN LU ; ANN-LII CHENG | BMC Cancer | 19 | 16 | |
2010 | E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: Possible correlation with stage and treatment response | Liu T.-Y.; SHEE-UAN CHEN ; SUNG-HSIN KUO ; ANN-LII CHENG ; CHUNG-WU LIN | Modern Pathology | 43 | 40 | |
2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
1997 | Early gastric cancer as a possible cause of cauda equina syndrome and disseminated intravascular coagulation | SHU-CHEN WEI ; Wong J.-M.; Chen C.-L.; ANN-LII CHENG ; Wang C.-Y.; Wang T.-H. | Digestive Endoscopy | 0 | 0 | |
2017 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 15 | 17 | |
2018 | Effect of glucocorticoid use on survival in patients with stage I–III breast cancer | CHING-HUNG LIN ; Chuang P.-Y.; You S.-L.; CHUN-JU CHIANG ; CHIUN-SHENG HUANG ; Wang M.-Y.; Chao M.; YEN-SHEN LU ; ANN-LII CHENG ; Tang C.-H. | Breast Cancer Research and Treatment | 8 | 8 | |
2004 | Effect of interleukin-1β and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma | MING-SHIANG WU ; CHIA-TUNG SHUN ; Huang S.-P.; ANN-LII CHENG ; Chen L.-T.; Lin J.-T. | Haematologica | 18 | 16 | |
2005 | Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors | CHIUN HSU ; CHIUNG-NIEN CHEN ; Chen L.-T.; Wu C.-Y.; FON-JOU HSIEH ; ANN-LII CHENG | Radiology | 23 | 22 | |
2023 | Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | DE-RUI HUANG ; BIN-CHI LIAO ; Hsu, Wei-Hsun; CHING-YAO YANG ; YEN-TING LIN ; SHANG-GIN WU ; TZU-HSIU TSAI ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; ANN-LII CHENG ; YING-CHUN SHEN | Oncology | |||
2005 | Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors | YEN-SHEN LU ; HUANG-CHUN LIEN ; Yeh P.-Y.; KUN-HUEI YEH ; Kuo M.-L.; SUNG-HSIN KUO ; ANN-LII CHENG | World Journal of Gastroenterology | 26 | 25 | |
2020 | Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma | Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG ; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. | Liver Cancer | 54 | 48 | |
2022 | Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN ; Youkstetter J.; Hazra S.; Sen S.; ANN-LII CHENG ; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. | British Journal of Cancer | 17 | 14 | |
2009 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | ANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. | The Lancet Oncology | 4852 | 4547 | |
2012 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | ANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. | European Journal of Cancer | 220 | 212 |